Comparison of the changes in adenine nucleotides of rat liver mitochondria induced by tamoxifen and 4-hydroxytamoxifen

Toxicology in Vitro

Volumn 17, Issue 5-6, 2003, Pages 663-670

  Cardoso, Carla M P ^a,b   Moreno, António J M ^b   Almeida, Leonor M ^a,b   Custódio, José B A ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

4 Hydroxytamoxifen; Adenine nucleotide translocase; Mitochondrial adenine nucleotides; Mitochondrial energetics; Phosphate carrier; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; ADENINE NUCLEOTIDE; ADENINE NUCLEOTIDE TRANSLOCASE; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; PHOSPHATE; TAMOXIFEN;

ANIMAL CELL; CATABOLISM; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DEPOLARIZATION; FEMALE; HYDROLYSIS; LIVER MITOCHONDRION; MALE; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; MITOCHONDRION SWELLING; NONHUMAN; PHOSPHATE TRANSPORT; PHOSPHORYLATION; RAT;

FORMICIDAE;

EID: 0242266954     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-2333(03)00106-1     Document Type: Conference Paper

References (38)

1. Bergan R.C., Reed E., Myers C.E., Headlee D., Brawley O., Cho H.K., Figg W.D., Tompkins A., Linehan W.M., Kohler D., Steinberg S.M., Blagosklonny M.V. A phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clinical Cancer Research. 5:1999;2366-2373.
2. Borgna J.-L., Rochefort H. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. The Journal of Biological Chemistry. 256:1981;859-868.
3. Brown G.C. Control of respiration and ATP synthesis in mammalian mitochondria cells. Biochemical Journal. 284:1992;1-13.
4. Cardoso C.M.P., Custódio J.B.A., Almeida L.M., Moreno A.J.M. Mechanisms of the deleterious effects of tamoxifen on mitochondrial respiration rate and phosphorylation efficiency. Toxicology and Applied Pharmacology. 176:2001;145-152.
5. Cardoso C.M.P., Moreno A.J.M., Almeida L.M., Custódio J.B.A. 4-Hydroxytamoxifen induces slight uncoupling of mitochondrial oxidative phosphorylation system in relation to the deleterious effects of tamoxifen. Toxicology. 179:2002;221-232.
6. Charlier C., Chariot A., Antoine N., Merville M., Gielen J., Castronovo V. Tamoxifen and its active metabolite inhibit growth of estrogen receptor-negative MDA-MB-435 cells. Biochemical Pharmacology. 49:1995;351-358.
7. Coezy E., Borgna J.L., Rochefort H. Tamoxifen and metabolites in MCF-7 cells. correlation between binding to estrogen receptor and inhibition of cell growth Cancer Research. 42:1982;317-323.
8. Couldwell W.T., Weiss M.H., Degiorgio C.M., Weimar L.P., Hinton D.R., Ehresmsan G.R., Conti P.S., Appuzo M.L.J., Korblith P., Detriboler N. Clinical and radiographic response in patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery. 32:1993;485-490.
9. Croxtall J.D., Emmas C., White J.O., Choudhary Q., Flower R.J. Tamoxifen inhibits growth of oestrogen receptor-negative A549 cells. Biochemical Pharmacology. 47:1994;197-202.
10. Daniel C.P., Gashell S.J., Nicholson R.I. The measurement of tamoxifen and metabolites in the rat and relationship to the response of DMBA-induced mammary tumors. European Journal of Cancer and Clinical Oncology. 20:1984;137-143.
11. Dietze E.C., Caldwell L.E., Grupin S.L., Mancini M., Seewaldt V.L. Tamoxifen bur not 4-hydroxytamoxifen initiates apoptosis in p53(-) normal human mammary epithelial cells by inducing mitochondrial depolarization. The Journal of Biological Chemistry. 276:2001;5384-5394.
12. Fattman C.L., An B., Sussman L., Dou Q.P. p53-independent dephosphorylation and cleavage of retinoblastoma protein during tamoxifen-induced apoptosis in human breast carcinoma cells. Cancer Letters. 130:1998;103-113.
13. Gornall A.G., Bardawill C.J., David M.M. Determination of serum proteins by means of the biuret reaction. The Journal of Biological Chemistry. 177:1949;751-766.
14. Gupta R.G., Milatovic D., Dettbarn W.-D. Depletion of energy metabolites following acetylcholinesterase inhibitor-induced status epilepticus:protection by antioxidants. NeuroToxicology. 22:2001;271-282.
15. Jordan V.C., Koch R., Langan S., McCague R. Ligand interaction at the estrogen receptor to program antiestrogen action. a study with non-steroidal compounds in vitro Endocrinology. 122:1988;1449-1454.
16. Jordan V.C. Long-term adjuvant tamoxifen therapy for breast cancer. Breast Cancer Research Treatment. 15:1990;125-136.
17. Klingenberg M. Metabolite transport in mitochondria. an example for the intracellular membrane function Campebell P.N., Dickens F. Essays in Biochemistry. 1970;119-159 Academic Press, New York.
18. Klingenberg M., Durand R., Guérin B. Analyses of the reactivity of SH-reagents with the mitochondrial phosphate carrier. European Journal of Biochemistry. 42:1974;135-150.
19. Klingenberg M., Giebe K., Scherer B. The binbing of atractylate and carboxyatractylate to mitochondria. European Journal of Biochemistry. 52:1975;351-363.
20. Laurence J., Cooke H., Sikder S.K. Effect of tamoxifen on regulation of viral replication and human immunodeficiency virus (HIV) long terminal repeat-directed transcription in cells chronically infected with HIV-1. Blood. 75:1990;696-703.
21. Lien E.A., Solheim E., Ueland P.M. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Research. 51:1991;4837-4844.
22. Luxo C., Jurado A.S., Custódio J.B.A., Madeira V.M.C. Use of Bacillus stearothermophilus as a model to study tamoxifen-membrane interactions. Toxicology in Vitro. 10:1996;463-471.
23. Madeira V.M.C., Antunes-Madeira M.C., Carvalho A.P. Activation energies of the ATPase activity of sarcoplasmic reticulum. Biochemical and Biophysical Research Communications. 58:1974;897-904.
24. Mandlekar S., Kong A.N. Mechanisms of tamoxifen-induced apoptosis. Apoptosis. 6:2001;469-477.
25. Moreno A.J.M., Madeira V.M.C. Mitochondrial bioenergetics as affected by DDT. Biochimica et Biophysica Acta. 1060:1991;166-174.
26. Neven P., Vernaeve H. Guidelines for monitoring patients taking tamoxifen treatment. Drug Safety. 22:2000;1-11.
27. Obrero M., Yu D.V., Shapiro D.J. Estrogen receptor-dependent and estrogen-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. The Journal of Biological Chemistry. 277:2002;45695- 45703.
28. Osborne C.K., Wiebe V.J., McGuire W.L., Ciocca D.R., DeGregorio M.W. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen resistant tumors from breast cancer patients. Journal of Clinical Oncology. 10:1992;304-310.
29. Pederson P.L. Mitochondrial events in the life and death of animal cells. a brief overview Journal of Bioenergetics and Biomembranes. 31:1999;291-304.
30. Perry R.R., Kang Y., Greaves B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and-independent human breast cancer cells. Annals of Surgical Oncology. 2:1995;238-245.
31. Radmacher M.D., Simon R. Estimation of tamoxifen's efficiency for preventing the formation and growth of breast tumors. Journal of the National Cancer Institute. 92:2000;48-53.
32. Roussel D., Chainier F., Rouanet J.-L., Barré H. Increase in the adenine nucleotide translocase content of duckling subsarcolemmal mitochondria during cold acclimation. FEBS Letters. 477:2000;141-144.
33. Sauvez F., Drouin D.S., Attia M., Bertheux H., Forster R. Cutaneously applied 4-hydroxytamoxifen is not carcinogenic in female rats. Carcinogenesis. 20:1999;843-850.
34. Stocchi V., Cucchiarini L., Chiarantini L., Palma P., Crescentini G. Simultaneous extraction and reverse-phase high-performance chromatographic determination of adenine and pyridine nucleotides in human red blood cells. Analytical Biochemistry. 146:1985;118-124.
35. Trope C., Marth C., Kaern J. Tamoxifen in the treatment of recurrent ovarian carcinoma. European Journal of Cancer. 36:2000;59-61.
36. Vignais P.V. Molecular and physiological aspects of adenine nucleotide transport in mitochondria. Biochimica et Biophysica Acta. 456:1976;1-38.
37. Wallace K.B., Starkov A.A. Mitochondrial targets of drug toxicity. Annual Review of Pharmacolology and Toxicology. 40:2000;353-388.
38. Zhou S., Starkov A., Froberg K., Leino R.L., Wallace K.B. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Research. 61:2001;771-777.